Recital 4, Regulation (EU) 2025/2017

In forcesince 8 Oct 2025

Upon request from the Commission, the Authority adopted a scientific opinion on 28 November 2024 on the nutritional safety and suitability of that specific protein hydrolysate in infant and follow-on formula [EFSA NDA Panel (2025). Nutritional safety and suitability of a specific protein hydrolysate manufactured by Fonterra Cooperative Group Ltd derived from a whey protein concentrate and used in infant formula and follow-on formula (EFSA Journal, 2025:23(1):e9160, https://doi.org/10.2903/j.efsa.2025.9160).]. In that opinion, the Authority concluded that the specific protein hydrolysate as described in the opinion is a nutritionally safe and a suitable protein source for use in infant and follow-on formula, as long as the formula in which it is used contains a minimum of 0,48 g/100 kJ (2,0 g/100 kcal) protein and complies with the remaining compositional criteria set out in Delegated Regulation (EU) 2016/127 and with the amino acid pattern contained in Section A of Annex III to that Regulation.